Safety, Immunogenicity and Efficacy Results of a 2-Component DT Acellular Pertussis Paediatric Vaccine and its Combinations with IPV and HIB Antigens

Comparison of the reactogenicity and imm

Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa–HBV–IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa–IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age

✍ J Arı́stegui; R Dal-Ré; J Dı́ez-Delgado; J Marés; J.M Casanovas; P Garcı́a-Corbe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Immunogenicity and safety of a combined

Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study

✍ Henry H. Bernstein; Fernando Noriega 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 685 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

## Background: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (glp-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. we aimed to compare combined insulin degludec-liraglutide (ideglira